- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07711418
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis (ZENITH AD-2)
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to- Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo.
The estimated participant overall duration is approximately 15 months.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Nektar Recruitment
- Número de teléfono: 855-482-8676
- Correo electrónico: StudyInquiry@nektar.com
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35203
- Reclutamiento
- Nektar Investigative Site
-
-
California
-
Oxnard, California, Estados Unidos, 93030
- Reclutamiento
- Nektar Investigative Site
-
Palmdale, California, Estados Unidos, 93551
- Reclutamiento
- Nektar Investigative Site
-
Sacramento, California, Estados Unidos, 95815
- Reclutamiento
- Nektar Investigative Site
-
-
Florida
-
Tamarac, Florida, Estados Unidos, 33321
- Reclutamiento
- Nektar Investigative Site
-
-
Georgia
-
Savannah, Georgia, Estados Unidos, 31406
- Reclutamiento
- Nektar Investigative Site
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Reclutamiento
- Nektar Investigative Site
-
-
Missouri
-
Kirksville, Missouri, Estados Unidos, 63501
- Reclutamiento
- Nektar Investigative Site
-
Lee's Summit, Missouri, Estados Unidos, 64064
- Reclutamiento
- Nektar Investigative Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89144
- Reclutamiento
- Nektar Investigative Site
-
-
New Jersey
-
Robbinsville, New Jersey, Estados Unidos, 08691
- Reclutamiento
- Nektar Investigative Site
-
-
New York
-
The Bronx, New York, Estados Unidos, 10455
- Reclutamiento
- Nektar Investigative Site
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43213
- Reclutamiento
- Nektar Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Male or female patients, ≥ 12 years of age on the day of signing the informed consent form and weighing ≥ 40 kg prior to randomization at Baseline
Chronic atopic dermatitis (AD) defined as onset of AD signs and symptoms
≥ 12 months prior to Screening as determined by the Investigator through patient interview and/or review of medical history at the Screening Visit
- Patients must meet the following AD severity criteria:
- IGA score ≥ 3 (scale of 0 to 4) at Screening and Baseline
- ≥ 10.0% of BSA involvement at Screening and Baseline
- EASI ≥ 16.0 at Screening and Baseline
- Are candidates for systemic therapy and have history, documented by a physician and/or the Investigator, of inadequate response to existing topical medications within 6 months preceding Screening, or history of intolerance to a topical therapy
- Provide written, informed consent to participate in the study and follow the study procedures, including compliance with the use of highly effective contraceptives
Exclusion Criteria:
- Are currently experiencing or have a history of concomitant skin conditions other than AD, including skin infection in the area affected by the patient's AD that requires treatment with systemic antimicrobial therapy
- Are currently experiencing or have a history of unstable course of AD
- History of chronic idiopathic urticaria at any time or urticaria from other causes within 4 weeks prior to randomization at the Baseline Visit.
- Have a history of TCS use suggestive of a high risk for topical corticosteroid (TCS) withdrawal
- Have received any of the following treatments at any time before Screening: aldesleukin; investigational IL-2 analog; systemic biologic; oral JAKi; or any prior investigational agent for AD
- Have a current or recent acute, active infection
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Blinded Induction Period: Rezpegaldesleukin every 2 weeks
Rezpegaldesleukin every 2 weeks during the induction period
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
Otros nombres:
|
|
Comparador de placebos: Blinded Induction Period: Placebo
Placebo every 2 weeks during the induction period
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
|
|
Experimental: Blinded Maintenance Period: Rezpegaldesleukin every 4 weeks
Rezpegaldesleukin every 4 weeks during the maintenance period
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
Otros nombres:
|
|
Experimental: Blinded Maintenance Period: Rezpegaldesleukin every 12 weeks
Rezpegaldesleukin every 12 weeks during the maintenance period
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
Otros nombres:
|
|
Comparador de placebos: Blinded Maintenance Period: Placebo
Placebo every 4 weeks during the maintenance period
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
|
|
Experimental: Open-Label Escape
Rezpegaldesleukin at a frequency determined by the investigator during the open-label escape
|
Forma farmacéutica: Solución inyectable Vía de administración: subcutánea
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24
Periodo de tiempo: Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24
Periodo de tiempo: Week 0 and Week 24
|
The IGA scale ranges from 0 to 4, with higher score indicating more severe disease.
|
Week 0 and Week 24
|
|
Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)
Periodo de tiempo: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
US only: Number of participants with a ≥ 75% reduction in EASI score from baseline at Week 24 (EASI-75)
Periodo de tiempo: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with a ≥ 90% reduction in EASI score from baseline at Week 24 (EASI-90)
Periodo de tiempo: Week 0 and Week 24
|
The EASI scores range from 0 to 72, with higher scores indicating more severe atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Periodo de tiempo: Week 0 and Week 6
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Itch numerical rating scale (NRS) in the subset of participants with a 4-point or greater Itch NRS at baseline
Periodo de tiempo: Week 0 and Week 24
|
The itch NRS goes from 0 to 10, with higher score indicating more severe itch.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Periodo de tiempo: Week 0 and Week 6
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 4-point or greater improvement in Skin Pain numerical rating scale (NRS) in the subset of participants with a 4-point or greater Skin Pain NRS at baseline
Periodo de tiempo: Week 0 and Week 24
|
The Skin Pain NRS goes from 0 to 10, with higher score indicating more severe pain.
|
Week 0 and Week 24
|
|
Number of participants at week 6 achieving a 1.25-point or greater improvement in Atopic Dermatitis Sleep Scale Question 1 (ADSS Q1) in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Periodo de tiempo: Week 0 and Week 6
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 6
|
|
Number of participants at week 24 achieving a 1.25-point or greater improvement in ADSS Q1 in the subset of participants with a 1.25-point or greater ADSS Q1 at baseline
Periodo de tiempo: Week 0 and Week 24
|
The ADSS Q1 goes from 0 to 4, with higher score indicating more difficulty sleeping.
|
Week 0 and Week 24
|
|
Change in Asthma Control Questionnaire-5 (ACQ-5) score from baseline at Week 24 in the subpopulation of patients with a 0.5-point or greater ACQ-5 at baseline
Periodo de tiempo: Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving a 0.5-point or greater improvement in ACQ-5 in the subset of participants with a 0.5-point or greater ACQ-5 at baseline
Periodo de tiempo: Week 0 and Week 24
|
The ACQ-5 goes from 0 to 6, with higher score indicating worse asthma control.
|
Week 0 and Week 24
|
|
Change in Sino-Nasal Outcome Test (SNOT-22) score from baseline at Week 24 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Periodo de tiempo: Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at Week 24 achieving a 8.9-point or greater reduction from baseline in SNOT-22 in the subpopulation of patients with an 8.9-point or greater SNOT-22 at baseline
Periodo de tiempo: Week 0 and Week 24
|
The SNOT-22 scores range from 0 to 110, with a higher score indicating more severe symptoms
|
Week 0 and Week 24
|
|
Number of participants at week 24 achieving an Adapted Investigator's Global Assessment (aIGA) response of 0 or 1
Periodo de tiempo: Week 0 and Week 24
|
The aIGA scale ranges from 0 to 1, with a lower score indicating improvement in atopic dermatitis.
|
Week 0 and Week 24
|
|
Number of participants with treatment emergent adverse events (TEAEs)
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent serious adverse events
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related serious adverse events
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment emergent adverse events of special interest
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with treatment related adverse events of special interest
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to treatment discontinuation
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose hold
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
|
|
Number of participants with TEAEs leading to dose modifications
Periodo de tiempo: Through participant study completion, approximately Week 56
|
Through participant study completion, approximately Week 56
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Study Director, Nektar Therapeutics
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- 25-358-10
- 2025 (Subvención/contrato del NIH de EE. UU.: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
- 2025-525129-11-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .